文献速递头颈部肿瘤放疗姑息放疗与转移瘤

头颈部黏膜黑色素瘤多模式治疗后的临床结局与失败模式

Clinical outcomes and patterns of failure of head and neck mucosal melanoma treated with multiple treatment modalities.
PubMed 文献 · Radiat Oncol · 2021-07-28

该回顾性研究分析了262例III-IVb期头颈部黏膜黑色素瘤(MMHN)患者,中位随访34.0个月,5年总生存(OS)、无远处转移生存(DMFS)和无病生存(DFS)分别为37.7%、30.2%和20.3%。远处转移是主要失败模式(40.8%),免疫/靶向治疗和手术与生存改善相关,AJCC第8版分期有效区分预后。

要点

  • 远处转移是MMHN治疗失败的主要原因,发生率为40.8%。
  • 免疫/靶向治疗和手术是改善MMHN生存的推荐治疗手段。
  • AJCC第8版分期系统能有效区分MMHN患者的预后。

核心结论

  • MMHN治疗失败的主要原因是远处转移,免疫/靶向治疗和手术推荐用于改善生存。

主要发现

  • 中位随访34.0个月(范围1-262个月),5年OS、DMFS和DFS分别为37.7%、30.2%和20.3%。
  • III期、IVA期和IVB期患者的5年OS率分别为67.0%、24.1%和8.3%(P < 0.001)。
  • 246例(93.9%)接受手术,149例(56.9%)接受化疗,69例(26.3%)接受免疫/靶向治疗,106例(40.5%)接受放疗。
  • 远处转移107例(40.8%),局部复发74例(28.2%),区域复发52例(19.8%)。
  • 多因素Cox回归显示,原发肿瘤部位、T分期和免疫/靶向治疗是OS的独立因素(均P < 0.05);放疗技术、T分期和N分期是DMFS的独立因素(均P < 0.05);T分期、N分期和手术是DFS的独立因素(均P < 0.05)。

关键数值与推荐

  • 5年OS、DMFS和DFS概率分别为37.7%、30.2%和20.3%。
  • III期、IVA期和IVB期患者的5年OS率分别为67.0%、24.1%和8.3%(P < 0.001)。
  • 远处转移、局部复发和区域复发率分别为40.8%、28.2%和19.8%。

临床怎么用

  • 对MMHN患者应重视远处转移的筛查和预防,免疫/靶向治疗和手术可考虑用于改善生存。

局限性

  • 回顾性研究设计,样本来自单中心,随访时间跨度大,可能存在选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study aims to analyze the clinical characteristics of head and neck mucosal melanoma (MMHN) and the effects of multiple treatment modalities on distant metastasis, recurrence and survival rates to provide a reference for the individualized treatment of MMHN. METHODS: We retrospectively reviewed 262 patients with stage III-IVb MMHN treated from March 1986 to November 2018 at our cancer center. RESULTS: The median follow-up time was 34.0 months (range 1-262 months). The 5-year overall survival (OS), distant metastasis-free survival (DMFS) and disease-free survival (DFS) probabilities were 37.7%, 30.2%, and 20.3%, respectively. The 5-year OS rates for patients with stage III, stage IVA, and stage IVB MMHN were 67.0%, 24.1% and 8.3%, respectively (P < 0.001). A total of 246 (93.9%) patients received surgery, 149 (56.9%) patients received chemotherapy, and 69 (26.3%) patients received immunologic/targeted therapy. A total of 106 (40.5%) patients were treated with radiotherapy: 9 were treated with preoperative radiotherapy, 93 were treated with postoperative radiotherapy, and 4 were treated with radiotherapy alone. In the multivariate Cox regression analysis, primary tumor site, T stage, and immunologic/targeted therapy were independent factors for OS (all P < 0.05). Irradiation technique, T stage, and N stage were independent prognostic factors for DMFS (all P < 0.05). T stage, N stage, and surgery were independent prognostic factors for DFS (all P < 0.05). Distant metastasis was observed in 107 of 262 patients (40.8%), followed by local [74 (28.2%)] and regional [52 (19.8%)] recurrence. CONCLUSIONS: The main reason for treatment failure in MMHN is distant metastasis. Immunologic/targeted therapy and surgery are recommended to improve the survival of MMHN. The American Joint Committee on Cancer (AJCC) 8th edition staging system for MMHN does stage this disease effectively.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xu QQ, Lai YZ, Huang ZL, et al. Clinical outcomes and patterns of failure of head and neck mucosal melanoma treated with multiple treatment modalities. Radiat Oncol. 2021. PMID: 34321026. doi:10.1186/s13014-021-01860-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。